What's all the fuss? Safety concerns about COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex).
Eric Wooltorton
Abstract
Eric Wooltorton
Abstract
Reason for posting: NSAIDs are useful in the treatment of several musculoskeletal conditions[1][1] and primary dysmenorrhea,[2][2] but they are associated with significant gastrointestinal events.[1][1] Selective cyclooxygenase-2 (COX-2) inhibitors such as rofecoxib (Vioxx) and celecoxib (Celebrex)
OpenAlex reports 21 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Reason for posting: NSAIDs are useful in the treatment of several musculoskeletal conditions[1][1] and primary dysmenorrhea,[2][2] but they are associated with significant gastrointestinal events.[1][1] Selective cyclooxygenase-2 (COX-2) inhibitors such as rofecoxib (Vioxx) and celecoxib (Celebrex)
Key concepts: Rofecoxib, Celecoxib, Medicine, Prostaglandin-Endoperoxide Synthase, Cyclooxygenase, Pharmacology, Chemistry, Enzyme